The History Behind The Drug-Device Combos Targeted By FTC

Of the 16 products whose Orange Book patent listings have been challenged by the FTC, six have no generic competitors and two faced first generic launches this year. A review of their patent and pricing battles shows the difficulties in developing generics for these complex drugs.

Inhalers
Inhalers whose patents were deemed improperly listed in the Orange Book by the Federal Trade Commission have retained market dominance with their device components. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics